Valeant Pharmaceuticals, Actavis, Mylan sales and marketing update

Valeant announced Actavis launched an authorized generic of Zovirax acyclovir in the U.S. after Mylan announced it received approval of its ANDA for the cold sore drug and launched its generic. Valeant will supply Actavis the generic product, and Actavis will market it and record all sales while Valeant will receive "a share of the economics," but other terms are not disclosed. Valeant also granted Actavis rights to co-promote Zovirax in the U.S. to obstetricians and gynecologists. Valeant said the timing of the generic approval was uncertain, but not unforeseen, and the company was prepared for its eventuality. The company expects the launch could affect its 2013 cash EPS by $0.30-$0.40. Valeant did not disclose 2012 sales for the synthetic nucleoside analog. ...